Biocon Biologics receives USFDA approval for cancer drug Jobevne

The USFDA has approved the cancer treatment medication Jobevne, which has allowed Biocon Biologics, the biosimilar division of Biocon, to increase its oncology portfolio.

Bevacizumab (marketed as Avastin) is a monoclonal antibody that is used in conjunction with chemotherapy to treat a variety of malignancies, including colorectal, lung, brain, kidney, and cervical cancers. Jobevne is a biosimilar of this medication. An intravenous infusion is used to give the medication.

In addition to OGIVRI (trastuzumab), FULPHILA (pegfilgrastim), and ABEVMY (an additional bevacizumab biosimilar approved in other markets), Jobevne is now the company's fourth cancer biosimilar in the US. In 2023, bevacizumab sales in the United States were approximately $2 billion.

“Jobevne is our seventh biosimilar approved in the US and a strong addition to our oncology portfolio. We look forward to working with all stakeholders to bring more treatment options to patients,” said Shreehas Tambe, CEO & Managing Director of Biocon Biologics Ltd.

The US market accounts for 40% of Biocon Biologics  total sales. As of right now, the company is developing 20 biosimilars, including insulins and monoclonal antibodies for a range of treatments. Along with its concentration on the US, Biocon Biologics is expanding through its business partners in areas like Australia and Japan, according to the sources.